» Articles » PMID: 38514185

Structural Plasticity of GABAergic Pallidothalamic Terminals in MPTP-Treated Parkinsonian Monkeys: A 3D Electron Microscopic Analysis

Overview
Journal eNeuro
Specialty Neurology
Date 2024 Mar 21
PMID 38514185
Authors
Affiliations
Soon will be listed here.
Abstract

The internal globus pallidus (GPi) is a major source of tonic GABAergic inhibition to the motor thalamus. In parkinsonism, the firing rate of GPi neurons is increased, and their pattern switches from a tonic to a burst mode, two pathophysiological changes associated with increased GABAergic pallidothalamic activity. In this study, we used high-resolution 3D electron microscopy to demonstrate that GPi terminals in the parvocellular ventral anterior nucleus (VApc) and the centromedian nucleus (CM), the two main GPi-recipient motor thalamic nuclei in monkeys, undergo significant morphometric changes in parkinsonian monkeys including (1) increased terminal volume in both nuclei; (2) increased surface area of synapses in both nuclei; (3) increased number of synapses/GPi terminals in the CM, but not VApc; and (4) increased total volume, but not number, of mitochondria/terminals in both nuclei. In contrast to GPi terminals, the ultrastructure of putative GABAergic nonpallidal terminals was not affected. Our results also revealed striking morphological differences in terminal volume, number/area of synapses, and volume/number of mitochondria between GPi terminals in VApc and CM of control monkeys. In conclusion, GABAergic pallidothalamic terminals are endowed with a high level of structural plasticity that may contribute to the development and maintenance of the abnormal increase in pallidal GABAergic outflow to the thalamus in the parkinsonian state. Furthermore, the evidence for ultrastructural differences between GPi terminals in VApc and CM suggests that morphologically distinct pallidothalamic terminals from single pallidal neurons may underlie specific physiological properties of pallidal inputs to VApc and CM in normal and diseased states.

References
1.
Magnin M, Morel A, Jeanmonod D . Single-unit analysis of the pallidum, thalamus and subthalamic nucleus in parkinsonian patients. Neuroscience. 2000; 96(3):549-64. DOI: 10.1016/s0306-4522(99)00583-7. View

2.
Mizukawa K, Sora Y, Ogawa N . Ultrastructural changes of the substantia nigra, ventral tegmental area and striatum in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mice. Res Commun Chem Pathol Pharmacol. 1990; 67(3):307-20. View

3.
Liu H, Ho P, Leung C, Pang S, Chang E, Choi Z . Aberrant mitochondrial morphology and function associated with impaired mitophagy and DNM1L-MAPK/ERK signaling are found in aged mutant Parkinsonian LRRK2 mice. Autophagy. 2020; 17(10):3196-3220. PMC: 8526027. DOI: 10.1080/15548627.2020.1850008. View

4.
Brustovetsky T, Khanna R, Brustovetsky N . Involvement of CRMP2 in Regulation of Mitochondrial Morphology and Motility in Huntington's Disease. Cells. 2021; 10(11). PMC: 8619197. DOI: 10.3390/cells10113172. View

5.
Vincent A, White K, Davey T, Philips J, Ogden R, Lawless C . Quantitative 3D Mapping of the Human Skeletal Muscle Mitochondrial Network. Cell Rep. 2019; 26(4):996-1009.e4. PMC: 6513570. DOI: 10.1016/j.celrep.2019.01.010. View